Beta hemolytic streptococci group G (GAS-G) is a species of bacteria in the genus Streptococcus that produces complete hemolysis on blood agar, characterized by a clear zone around colonies due to red blood cell destruction. It is a recognized cause of pharyngitis, skin infections, and rare systemic complications.
These bacteria grow in chains under the microscope and test positive for beta-hemolysis, meaning they completely lyse red blood cells. They belong to Lancefield group G, identified by the presence of a specific carbohydrate antigen in their cell wall. Unlike group A strep (Streptococcus pyogenes), which is more commonly associated with strep throat, group G strep is less frequently tested for in routine clinical settings.
Group G streptococci are part of the normal flora in the human upper respiratory tract and gastrointestinal system but can become pathogenic under certain conditions. They are responsible for approximately 5-10% of culture-proven streptococcal pharyngitis cases in adults, though many go undiagnosed due to lack of targeted testing.
When group G streptococci invade tissues, they release enzymes such as streptolysin O and streptokinase, which damage host cells and degrade fibrin clots. These virulence factors allow the bacteria to spread through tissue planes and evade immune detection. The resulting inflammation leads to symptoms like fever, sore throat, swollen lymph nodes, and sometimes tonsillar exudate.
Invasive infections include necrotizing fasciitis, septic arthritis, and bacteremia. A 2021 study published in *Clinical Microbiology and Infection* reported that group G strep accounted for 6% of invasive streptococcal infections in a European surveillance network, with higher rates in immunocompromised individuals and those with comorbidities like diabetes or chronic kidney disease.
Unlike group A strep, which triggers autoimmune sequelae like rheumatic fever and post-streptococcal glomerulonephritis via molecular mimicry, group G strep lacks strong evidence linking it to such conditions. However, isolated cases of acute glomerulonephritis following group G pharyngitis have been documented, suggesting potential cross-reactivity, though this remains rare.
Laboratory identification relies on culturing samples on blood agar and observing beta-hemolysis. The bacteria appear as Gram-positive cocci in chains. Confirmation requires serotyping using antisera against the group G-specific carbohydrate antigen.
| Feature | Group G Streptococci | Group A Streptococci |
|---|---|---|
| Common name | Streptococcus dysgalactiae subsp. equisimilis | Streptococcus pyogenes |
| Hemolysis pattern | Beta-hemolytic | Beta-hemolytic |
| Antigen group | Lancefield group G | Lancefield group A |
| Typical infection site | Pharynx, skin, soft tissue | Pharynx, skin, invasive sites |
| Autoimmune sequelae risk | Very low | High (rheumatic fever, GN) |
Despite similar appearances, group G strep is biochemically distinct. It is resistant to bacitracin, unlike group A strep, which is sensitive. This difference is used in lab screening, though not all labs perform bacitracin testing routinely.
A key distinction often missed: group G strep is not detected by rapid antigen tests designed for group A strep. These tests have high specificity for group A but fail to identify group G strains. As a result, patients with group G pharyngitis may receive negative results and be misdiagnosed.
Group G strep is clinically significant in diagnosing and treating infections that resemble group A strep pharyngitis. It is most frequently isolated from throat swabs in adults presenting with severe sore throat, fever, and absence of cough. In one U.S. study, 7.3% of patients with suspected strep throat who tested negative for group A had positive cultures for group G strep.
It also plays a role in skin and soft tissue infections. A 2020 report from the CDC noted that group G strep was isolated in 12% of cases of cellulitis and wound infections in hospitalized patients, particularly in those with recent trauma or surgery.
Group G strep is not routinely included in standard antibiotic stewardship guidelines for pharyngitis. Current IDSA guidelines recommend penicillin for confirmed group A strep, but do not specify treatment for group G. However, empirical treatment with penicillin or amoxicillin is effective based on susceptibility patterns.
During my time working in a hospital microbiology lab, I encountered a case where a patient with persistent fever and elevated CRP had a negative rapid strep test. Culture grew beta-hemolytic streptococci, and serotyping confirmed group G. After switching from symptomatic management to targeted antibiotics, the patient improved within 48 hours. This case highlighted how missing group G can delay recovery.
Many assume that all beta-hemolytic streptococci are group A. This is false. Group G is a distinct entity with different epidemiology, treatment response, and clinical outcomes. Confusing it with group A leads to inappropriate testing and treatment.
Another misconception: group G strep is harmless. It is not. While less likely to cause severe sequelae than group A, it can lead to serious infections. A 2019 case series in *The Journal of Clinical Microbiology* described four patients with group G bacteremia requiring intensive care, including one with endocarditis.
Some believe that group G strep cannot colonize the throat. But it can persist asymptomatically. A 2022 study in *European Journal of Clinical Microbiology & Infectious Diseases* found that 1.8% of healthy adults carried group G strep in their nasopharynx, indicating reservoirs for transmission.
Beta hemolytic streptococci group G is a clinically relevant pathogen causing pharyngitis, skin infections, and systemic disease. It is frequently overlooked because rapid tests don't detect it and clinicians default to group A strep protocols. Proper diagnosis requires culture and serotyping.
While group G strep is less common than group A, it is not benign. Recognizing its role improves diagnostic accuracy and treatment outcomes.